Status:
COMPLETED
Safety And Efficacy Of Lyrica (Regulatory Post Marketing Commitment Plan)
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Neuralgia
Eligibility:
All Genders
Brief Summary
The objective of this Investigation is to evaluate the safety and efficacy of Lyrica in medical practice. Also, occurrence of unknown and known adverse drug reactions (ADRs) in subjects treated with L...
Detailed Description
All the patients whom an investigator prescribes the first Lyrica® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the ...
Eligibility Criteria
Inclusion
- Patients need to be administered Lyrica® in order to be enrolled in the surveillance.
Exclusion
- Patients not administered Lyrica®.
Key Trial Info
Start Date :
February 5 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2017
Estimated Enrollment :
3827 Patients enrolled
Trial Details
Trial ID
NCT01256593
Start Date
February 5 2011
End Date
July 31 2017
Last Update
September 15 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.